Cargando…
Neuroleptic malignant-like syndrome associated multiple system atrophy: report on three cases
BACKGROUND: Multiple system atrophy (MSA) associated with neuroleptic malignant-like syndrome (NMLS) is rare and few cases have been described in the literature. CASE PRESENTATION: In the present study, three patients with MSA associated with NMLS were analyzed from January 2012 to January 2020 to c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876065/ https://www.ncbi.nlm.nih.gov/pubmed/35216572 http://dx.doi.org/10.1186/s12883-022-02583-8 |
_version_ | 1784658080534888448 |
---|---|
author | Lin, Yan Ma, Lin Zhang, Nan Li, Ruihua Jiang, Wenjing |
author_facet | Lin, Yan Ma, Lin Zhang, Nan Li, Ruihua Jiang, Wenjing |
author_sort | Lin, Yan |
collection | PubMed |
description | BACKGROUND: Multiple system atrophy (MSA) associated with neuroleptic malignant-like syndrome (NMLS) is rare and few cases have been described in the literature. CASE PRESENTATION: In the present study, three patients with MSA associated with NMLS were analyzed from January 2012 to January 2020 to characterize their clinical presentations. Data collected from the patients for analysis included general patient history, the fluctuation and severity of disease symptoms, the indicated therapies and disease progression at follow-up. All patients had histories of sudden withdrawal or reduction of levodopa prior to the onset of symptoms. Clinical presentations were characterized by hyperthermia, autonomic dysfunction, worsening of extrapyramidal symptoms, and elevated serum creatine kinase (CK) levels. During hospitalization, one patient rapidly progressed and died, while the other two patients were successfully treated. CONCLUSIONS: Early diagnosis and treatment are very important for patient outcomes in NMLS. Notably, the correct dose and time of administration of dopaminergic medication may be key in treating NMLS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12883-022-02583-8. |
format | Online Article Text |
id | pubmed-8876065 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88760652022-02-28 Neuroleptic malignant-like syndrome associated multiple system atrophy: report on three cases Lin, Yan Ma, Lin Zhang, Nan Li, Ruihua Jiang, Wenjing BMC Neurol Case Report BACKGROUND: Multiple system atrophy (MSA) associated with neuroleptic malignant-like syndrome (NMLS) is rare and few cases have been described in the literature. CASE PRESENTATION: In the present study, three patients with MSA associated with NMLS were analyzed from January 2012 to January 2020 to characterize their clinical presentations. Data collected from the patients for analysis included general patient history, the fluctuation and severity of disease symptoms, the indicated therapies and disease progression at follow-up. All patients had histories of sudden withdrawal or reduction of levodopa prior to the onset of symptoms. Clinical presentations were characterized by hyperthermia, autonomic dysfunction, worsening of extrapyramidal symptoms, and elevated serum creatine kinase (CK) levels. During hospitalization, one patient rapidly progressed and died, while the other two patients were successfully treated. CONCLUSIONS: Early diagnosis and treatment are very important for patient outcomes in NMLS. Notably, the correct dose and time of administration of dopaminergic medication may be key in treating NMLS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12883-022-02583-8. BioMed Central 2022-02-25 /pmc/articles/PMC8876065/ /pubmed/35216572 http://dx.doi.org/10.1186/s12883-022-02583-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Lin, Yan Ma, Lin Zhang, Nan Li, Ruihua Jiang, Wenjing Neuroleptic malignant-like syndrome associated multiple system atrophy: report on three cases |
title | Neuroleptic malignant-like syndrome associated multiple system atrophy: report on three cases |
title_full | Neuroleptic malignant-like syndrome associated multiple system atrophy: report on three cases |
title_fullStr | Neuroleptic malignant-like syndrome associated multiple system atrophy: report on three cases |
title_full_unstemmed | Neuroleptic malignant-like syndrome associated multiple system atrophy: report on three cases |
title_short | Neuroleptic malignant-like syndrome associated multiple system atrophy: report on three cases |
title_sort | neuroleptic malignant-like syndrome associated multiple system atrophy: report on three cases |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876065/ https://www.ncbi.nlm.nih.gov/pubmed/35216572 http://dx.doi.org/10.1186/s12883-022-02583-8 |
work_keys_str_mv | AT linyan neurolepticmalignantlikesyndromeassociatedmultiplesystematrophyreportonthreecases AT malin neurolepticmalignantlikesyndromeassociatedmultiplesystematrophyreportonthreecases AT zhangnan neurolepticmalignantlikesyndromeassociatedmultiplesystematrophyreportonthreecases AT liruihua neurolepticmalignantlikesyndromeassociatedmultiplesystematrophyreportonthreecases AT jiangwenjing neurolepticmalignantlikesyndromeassociatedmultiplesystematrophyreportonthreecases |